Drug intelligence / Profile preview

Adze-1.17.HPV.4

Development stage: Preclinical
Lead developer: Adze Biotechnology
Modality: Vaccines & Immunotherapeutics
Administration: Systemic, Intra-tumoral

Overview

Adze-1.17.HPV.4 is a preclinical-stage therapeutic vaccine developed by Adze Biotechnology, Inc., targeting neoplasms and urogenital diseases, with active indications in head and neck neoplasms and uterine cervical cancer[1][4]. It is part of the broader Adze-1.17 oncolytic immunotherapy platform, which is designed for systemic or intra-tumoral delivery of immune-stimulatory transgenes and checkpoint inhibitors to solid tumors[3]. The specific mechanism of action for Adze-1.17.HPV.4 has not been disclosed in public sources as of the latest updates.

Beyond the preview

Go deeper on Adze-1.17.HPV.4.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Adze-1.17.HPV.4.

Explore the full profile